Better cells for better science, and better outcomes for patients.

We help scientists and biopharma teams measure how closely their cells match the target identity and how to improve them when they fall short.

Better cell identity reduces failure in drug discovery, supports stronger disease models, and helps advance cell-based therapies.

A CapyBio scientist at the bench — In the lab

Better therapies begin with better cells.

Drug discovery, disease modeling, and cell-based applications still depend on cells that often miss human biology. Immature, inconsistent, or incomplete cells make every downstream decision less certain.

Our founders came from cell biology, computation, and cell identity. They saw that measuring and improving identity could create better cells across research, testing, and regenerative medicine.

Interest in co-founder Samantha Morris’s academic technologies made the opportunity clear: move these tools beyond one lab and into the hands of teams building next-generation therapies.

The mission is personal. More breakthroughs are possible when the cells behind research and therapy are better understood and better built. CapyBio exists to strengthen that foundation.